321 related articles for article (PubMed ID: 26765686)
1. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
Kim H; Tarhuni A; Abd Elmageed ZY; Boulares AH
J Transl Med; 2015 Jul; 13():233. PubMed ID: 26183824
[TBL] [Abstract][Full Text] [Related]
5. IGF-1R as an anti-cancer target--trials and tribulations.
Chen HX; Sharon E
Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
[TBL] [Abstract][Full Text] [Related]
6. New strategies in ewing sarcoma: lost in translation?
Arnaldez FI; Helman LJ
Clin Cancer Res; 2014 Jun; 20(12):3050-6. PubMed ID: 24756371
[TBL] [Abstract][Full Text] [Related]
7. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.
Santoro M; Lamhamedi-Cherradi SE; Menegaz BA; Ludwig JA; Mikos AG
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10304-9. PubMed ID: 26240353
[TBL] [Abstract][Full Text] [Related]
8. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
11. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
12. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
13. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
16. Ewing's sarcoma: overcoming the therapeutic plateau.
Subbiah V; Kurzrock R
Discov Med; 2012 Jun; 13(73):405-15. PubMed ID: 22742646
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
18. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
[TBL] [Abstract][Full Text] [Related]
19. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
